VSIR and familial pancreatic carcinoma: The anti-tumor immunity following anti-VISTA treatment is suspected to be a consequence of altered macrophage polarization towards the inflammatory M1 phenotype (43), as VISTA’s biological function in pancreatic cancer is still unclear (106).